Antithrombotic Therapy in Cerebral Cavernous Malformations: A Systematic Review, Meta-Analysis, and Network Meta-Analysis

被引:5
作者
Musmar, Basel [2 ]
Salim, Hamza [5 ]
Abdelgadir, Jihad [2 ]
Spellicy, Samantha [2 ]
Adeeb, Nimer [5 ]
Zomorodi, Ali [2 ]
Friedman, Allan [2 ]
Awad, Issam [3 ]
Jabbour, Pascal M. [4 ]
Hasan, David M. [1 ,2 ]
机构
[1] Duke Univ Hosp, 40 Duke Med Circle, Durham, NC 27710 USA
[2] Duke Univ Hosp, Dept Neurosurg, Durham, NC USA
[3] Univ Chicago Med, Dept Neurosurg, Chicago, IL USA
[4] Thomas Jefferson Univ Hosp, Dept Neurosurg, Philadelphia, PA USA
[5] Louisiana State Univ Hosp, Dept Neurosurg, Shreveport, LA USA
来源
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2024年 / 13卷 / 06期
关键词
antithrombotic; CCM; cerebral cavernous malformation; intracranial hemorrhage; INTRACRANIAL VASCULAR MALFORMATION; BLEEDING RISK; STATIN; BRAIN;
D O I
10.1161/JAHA.123.032910
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Cerebral cavernous malformations are complex vascular anomalies in the central nervous system associated with a risk of intracranial hemorrhage. Traditional guidelines have been cautious about the use of antithrombotic therapy in this patient group, citing concerns about potential bleeding risk. However, recent research posits that antithrombotic therapy may actually be beneficial. This study aims to clarify the association between antithrombotic therapy, including antiplatelet and anticoagulant medications, and the risk of intracranial hemorrhage in patients with cerebral cavernous malformations. METHODS AND RESULTS: A comprehensive literature search was conducted in PubMed, Web of Science, and Scopus databases, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Nine single-center, nonrandomized cohort studies involving 2709 patients were included. Outcomes were analyzed using random- effects model, and a network meta-analysis was conducted for further insight. Of the 2709 patients studied, 388 were on antithrombotic therapy. Patients on antithrombotic therapy had a lower risk of presenting with intracranial hemorrhage (odds ratio [OR], 0.56 [95% CI, 0.45-0.7]; P<0.0001). In addition, the use of antithrombotic therapy was associated with lower risk of intracranial hemorrhage from a cerebral cavernous malformation on follow-up (OR, 0.21 [95% CI, 0.13-0.35]; P<0.0001). A network meta-analysis revealed a nonsignificant OR of 0.73 (95% CI, 0.23-2.56) when antiplatelet therapy was compared with anticoagulant therapy. CONCLUSIONS: Our study explores the potential benefits of antithrombotic therapy in cerebral cavernous malformations. Although the analysis suggests a possible role for antithrombotic agents, it is critical to note that the evidence remains preliminary. Fundamental biases in study design, such as ascertainment and assignment bias, limit the weight of our conclusions. Therefore, our findings should be considered hypothesis- generating and not definitive for clinical practice change.
引用
收藏
页数:9
相关论文
共 30 条
[1]   Thrombus and encapsulated hematoma in cerebral cavernous malformations [J].
Abe, M ;
Fukudome, K ;
Sugita, Y ;
Oishi, T ;
Tabuchi, K ;
Kawano, T .
ACTA NEUROPATHOLOGICA, 2005, 109 (05) :503-509
[2]   Prospective, population-based detection of intracranial vascular malformations in adults - The Scottish Intracranial Vascular Malformation Study (SIVMS) [J].
Al-Shahi, R ;
Bhattacharya, JJ ;
Currie, DG ;
Papanastassiou, V ;
Ritchie, V ;
Roberts, RC ;
Sellar, RJ ;
Warlow, CP .
STROKE, 2003, 34 (05) :1163-1169
[3]   Antithrombotic medication and bleeding risk in patients with cerebral cavernous malformations: a cohort study [J].
Bervini, David ;
Jaeggi, Christian ;
Mordasini, Pasquale ;
Schucht, Philippe ;
Raabe, Andreas .
JOURNAL OF NEUROSURGERY, 2019, 130 (06) :1922-1930
[4]   To use or not to use antithrombotics in unruptured cerebrovascular malformations? A systematic review focusing on this clinical and surgical dilemma [J].
Bianconi, Andrea ;
Ceraudo, Marco ;
Nico, Elsa ;
Minardi, Massimiliano ;
Allevi, Mario ;
Prior, Alessandro ;
Garbossa, Diego ;
Zona, Gianluigi ;
Fiaschi, Pietro .
NEUROSURGICAL FOCUS, 2023, 55 (04)
[5]   Overview of cerebral cavernous malformations: comparison of treatment approaches [J].
Bubenikova, Adela ;
Skalicky, Petr ;
Benes, Vladimir, Jr. ;
Benes Sr, Vladimir Sr ;
Bradac, Ondrej .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (05) :475-480
[6]   Safety of deep venous thrombosis prophylaxis with low-molecular-weight heparin in brain surgery. Prospective study on 746 patients [J].
Chibbaro, Salvatore ;
Tacconi, Leonello .
SURGICAL NEUROLOGY, 2008, 70 (02) :117-121
[7]   Differences between intracranial vascular malformation types in the characteristics of their presenting haemorrhages: prospective, population-based study [J].
Cordonnier, C. ;
Salman, R. Al-Shahi ;
Bhattacharya, J. J. ;
Counsell, C. E. ;
Papanastassiou, V. ;
Ritchie, V. ;
Roberts, R. C. ;
Sellar, R. J. ;
Warlow, C. .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2008, 79 (01) :47-51
[8]   A Call for Rigorous Study of Statins in Resolution of Cerebral Cavernous Malformation Pathology [J].
Eisa-Beygi, Shahram ;
Wen, Xiao-Yan ;
Macdonald, R. Loch .
STROKE, 2014, 45 (06) :1859-1861
[9]  
Flemming K., 2018, 4 BELLARIA NEUROVASC
[10]   Cavernous Malformation Hemorrhagic Presentation at Diagnosis Associated with Low 25-Hydroxy-Vitamin D Level [J].
Flemming, Kelly D. ;
Kumar, Shivram ;
Brown, Robert D., Jr. ;
Singh, Ravinder J. ;
Whitehead, Kevin ;
McCreath, Lauren ;
Lanzino, Giuseppe .
CEREBROVASCULAR DISEASES, 2020, 49 (02) :216-222